Cargando…
PD-L1(+)NEUT, Foxp3(+)Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma
Background: This presented study was aimed to evaluate the diagnostic and prognostic value of PD-L1(+)Neutrophils (PD-L1(+)NEUT) and neutrophil to lymphocyte ratio (NLR) based on our previous experience of Foxp3(+)Treg in transplantation. Methods: the NLR cutoff value of 1.79 was used to include 136...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493317/ https://www.ncbi.nlm.nih.gov/pubmed/34605709 http://dx.doi.org/10.1177/15330338211045820 |
_version_ | 1784579098408910848 |
---|---|
author | Zhou, Lin Wang, Jing Lyu, Shao-cheng Pan, Li-chao Shi, Xian-jie Du, Guo-sheng He, Qiang |
author_facet | Zhou, Lin Wang, Jing Lyu, Shao-cheng Pan, Li-chao Shi, Xian-jie Du, Guo-sheng He, Qiang |
author_sort | Zhou, Lin |
collection | PubMed |
description | Background: This presented study was aimed to evaluate the diagnostic and prognostic value of PD-L1(+)Neutrophils (PD-L1(+)NEUT) and neutrophil to lymphocyte ratio (NLR) based on our previous experience of Foxp3(+)Treg in transplantation. Methods: the NLR cutoff value of 1.79 was used to include 136 cases from the 204 patients with hepatocellular carcinoma (HCC) confirmed by clinical pathology, which were divided into highly-moderately and poorly differentiated HCC groups. The expressions of PD-L1(+)NEUT and Foxp3(+)Treg in peripheral blood and cancer tissue were detected with flow cytometry, meanwhile, PD-L1 and Foxp3 expressed in carcinoma and para-carcinoma tissues were marked by immunohistochemistry. Survival rates, including overall survival and disease-free survival, were calculated by the Kaplan–Meier curve and evaluated with the log-rank test. Finally, Cox risk regression model was used to analyze the independent risk factors for prognostic survival. Results: The level of PD-L1(+)NEUT, Foxp3(+)Treg, and NLR in peripheral blood of patients with poorly differentiated HCC were significantly increased (all P < .001). Both PD-L1(+)NEUT and NLR were positively correlated with Foxp3(+)Treg (r = 0.479, P = .0017; r = 0.58, P < .0001). The level of PD-L1(+)NEUT and Foxp3(+)Treg as well as PD-L1 and Foxp3 in cancer tissue and patients with poorly differentiated HCC were obviously increased (all P < .01), respectively. Cox regression analysis indicated that PD-L1(+)NEUT, NLR, and Foxp3(+)Treg were independent risk factors for the prognosis (P = .000, .000, .006) with a RR and 95%CI of 2.704-(2.155-3.393), 3.139-(2.361-4.173), 1.409-(1.105-1.798), respectively. Conclusion: PD-L1(+)NEUT, NLR, and Foxp3(+)Treg are independent risk factors for prognosis which maybe new marker of lower survival benefits. |
format | Online Article Text |
id | pubmed-8493317 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-84933172021-10-07 PD-L1(+)NEUT, Foxp3(+)Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma Zhou, Lin Wang, Jing Lyu, Shao-cheng Pan, Li-chao Shi, Xian-jie Du, Guo-sheng He, Qiang Technol Cancer Res Treat Original Article Background: This presented study was aimed to evaluate the diagnostic and prognostic value of PD-L1(+)Neutrophils (PD-L1(+)NEUT) and neutrophil to lymphocyte ratio (NLR) based on our previous experience of Foxp3(+)Treg in transplantation. Methods: the NLR cutoff value of 1.79 was used to include 136 cases from the 204 patients with hepatocellular carcinoma (HCC) confirmed by clinical pathology, which were divided into highly-moderately and poorly differentiated HCC groups. The expressions of PD-L1(+)NEUT and Foxp3(+)Treg in peripheral blood and cancer tissue were detected with flow cytometry, meanwhile, PD-L1 and Foxp3 expressed in carcinoma and para-carcinoma tissues were marked by immunohistochemistry. Survival rates, including overall survival and disease-free survival, were calculated by the Kaplan–Meier curve and evaluated with the log-rank test. Finally, Cox risk regression model was used to analyze the independent risk factors for prognostic survival. Results: The level of PD-L1(+)NEUT, Foxp3(+)Treg, and NLR in peripheral blood of patients with poorly differentiated HCC were significantly increased (all P < .001). Both PD-L1(+)NEUT and NLR were positively correlated with Foxp3(+)Treg (r = 0.479, P = .0017; r = 0.58, P < .0001). The level of PD-L1(+)NEUT and Foxp3(+)Treg as well as PD-L1 and Foxp3 in cancer tissue and patients with poorly differentiated HCC were obviously increased (all P < .01), respectively. Cox regression analysis indicated that PD-L1(+)NEUT, NLR, and Foxp3(+)Treg were independent risk factors for the prognosis (P = .000, .000, .006) with a RR and 95%CI of 2.704-(2.155-3.393), 3.139-(2.361-4.173), 1.409-(1.105-1.798), respectively. Conclusion: PD-L1(+)NEUT, NLR, and Foxp3(+)Treg are independent risk factors for prognosis which maybe new marker of lower survival benefits. SAGE Publications 2021-10-04 /pmc/articles/PMC8493317/ /pubmed/34605709 http://dx.doi.org/10.1177/15330338211045820 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Zhou, Lin Wang, Jing Lyu, Shao-cheng Pan, Li-chao Shi, Xian-jie Du, Guo-sheng He, Qiang PD-L1(+)NEUT, Foxp3(+)Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma |
title | PD-L1(+)NEUT, Foxp3(+)Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma |
title_full | PD-L1(+)NEUT, Foxp3(+)Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma |
title_fullStr | PD-L1(+)NEUT, Foxp3(+)Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma |
title_full_unstemmed | PD-L1(+)NEUT, Foxp3(+)Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma |
title_short | PD-L1(+)NEUT, Foxp3(+)Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma |
title_sort | pd-l1(+)neut, foxp3(+)treg, and nlr as new prognostic marker with low survival benefits value in hepatocellular carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493317/ https://www.ncbi.nlm.nih.gov/pubmed/34605709 http://dx.doi.org/10.1177/15330338211045820 |
work_keys_str_mv | AT zhoulin pdl1neutfoxp3tregandnlrasnewprognosticmarkerwithlowsurvivalbenefitsvalueinhepatocellularcarcinoma AT wangjing pdl1neutfoxp3tregandnlrasnewprognosticmarkerwithlowsurvivalbenefitsvalueinhepatocellularcarcinoma AT lyushaocheng pdl1neutfoxp3tregandnlrasnewprognosticmarkerwithlowsurvivalbenefitsvalueinhepatocellularcarcinoma AT panlichao pdl1neutfoxp3tregandnlrasnewprognosticmarkerwithlowsurvivalbenefitsvalueinhepatocellularcarcinoma AT shixianjie pdl1neutfoxp3tregandnlrasnewprognosticmarkerwithlowsurvivalbenefitsvalueinhepatocellularcarcinoma AT duguosheng pdl1neutfoxp3tregandnlrasnewprognosticmarkerwithlowsurvivalbenefitsvalueinhepatocellularcarcinoma AT heqiang pdl1neutfoxp3tregandnlrasnewprognosticmarkerwithlowsurvivalbenefitsvalueinhepatocellularcarcinoma |